3 ms·
I think this article is a bit more nuanced based on what they are seeing on the ground. Derek brings up good points about background rates, but papers over some
by ttesttom 6y ago
I think this article is a bit more nuanced based on what they are seeing on the ground. Derek brings up good points about background rates, but papers over some things. It's a complex picture and the below article paints it well.
Also scientists in Norway claim they found the mechanism that causes it.
https://www.sciencemag.org/news/2021/03/it-s-very-special-picture-why-vaccine-safety-experts-put-brakes-astrazeneca-s-covid-19 https://www.sciencemag.org/news/2021/03/it-s-very-special-pi...
https://www.vg.no/nyheter/innenriks/i/KyGv2G/professor-says-cause-of-rare-bloodclots-in-people-vaccinated-with-astrazeneca-has-been-found https://www.vg.no/nyheter/innenriks/i/KyGv2G/professor-says-...
- blywi 6y agoI was going to post the same link, as I also feel that this article is more nuanced. There is also a twitter thread by one of the article's authors summarizing the article and discussing some additional information. https://twitter.com/kakape/status/1372315648894844940 https://twitter.com/kakape/status/1372315648894844940
- testplzignore 6y ago> AstraZeneca supplies Europe with vaccine from several plants, however, and EMA could not say whether all of the batches involved came from the same facility. Is there an answer to this yet? The batch that a particular person's dose came from is carefully documented (or at least should be - it is in the USA).
- ttesttom 6y agoIn the EMA statement from today they said: > there is no evidence of a problem related to specific batches of the vaccine or to particular manufacturing sites; https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazene...